Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

Sarepta Therapeutics experienced one of its most severe trading sessions in recent history, with shares collapsing by more than 33%. This dramatic sell-off occurred after the company announced that its pivotal Phase 3 ESSENCE trial for Duchenne muscular dystrophy therapies failed to meet primary objectives. The stock price plummeted from $24.46 to $16.20, reflecting widespread investor anxiety regarding the company’s future regulatory pathway.

The ESSENCE trial results delivered a devastating blow to Sarepta’s development program. This global Phase 3 study evaluating both AMONDYS 45 and VYONDYS 53 did not achieve its primary endpoint of demonstrating improved motor function in patients. While company representatives highlighted what they described as “positive and encouraging trends” observed after 96 weeks Read more...